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ABSTRACT
Background
Arab American immigrants are an understudied minority in the United States due to their
invisibility under the White racial group in census data. As such, there is little health research
regarding their preventative behaviors, including for cervical cancer, a preventable but fatal
illness. Human papillomavirus infection (HPV), a sexually-transmitted infection which can be
prevented through the administration of a 3 regimen vaccine between the ages of 9 and 26 is
the primary known cause. This study assesses the relationship between region of birth and HPV
vaccination.
Methods
Utilizing data from the National Health Interview Survey (NHIS) from 2016, 2017, and 2018, we
assessed the relationship between region of birth and HPV vaccination. The primary outcomes
of interest were ever having received the vaccine, how many shots of the vaccine were
received, and at what age the first shot of the vaccine was received. The demographic variables
of interest, or covariates, were age, education level, years spent in the US, marital status,
health insurance coverage, and employment status. A frequency analysis was conducted for all
variables of interest and odds ratios were calculated for the primary outcomes of interest after
controlling for covariates.
Results
Arab Americans had a lower odds (OR = 0.435) of ever having received the HPV vaccine
compared with participants born in the US than those born in Europe or Other regions. Further,
Arab Americans had a lower odds (OR = 0.122) of completing the 3-shot vaccine regimen as
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well. Not a single Arab American participant reported receiving the first shot on time (below the
age of 15). Due to a lack of data, the latter two outcomes were not statistically significant.
Conclusions
Overall, the Arab American minority has a significantly lower odds of ever having received the
HPV vaccine than their White counterparts and a lower odds of completing the vaccine regimen
or receiving the first shot of the vaccine on time. This study validates the existence of health
disparities and exemplifies the need for more research targeted towards this minority group.
Key Words: HPV, cervical cancer, vaccine, Arab American
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INTRODUCTION
Background
As any minority group in the United States, specifically immigrant group, Arab
Americans face unique sociocultural barriers to receiving healthcare and participating in
preventative health behaviors (Dallo & Kindratt, 2015; Echeverria & Carrasquillo, 2006; Singh &
Hiatt, 2006). However, unlike many other minority groups, Arab Americans are not as
thoroughly studied in preventative health literature, or even health literature more generally
(Abboud et al., 2017). A primary cause for this discrepancy in a lack of health knowledge is the
categorization of Arab Americans as “White” in the overwhelming majority of census data
(Abboud et al., 2017). This phenomenon tends to make the Arab American minority invisible in
research documenting health disparities among racial and ethnic cohorts.
One of the understudied health disparities among Arab American women is cervical
cancer, particularly prevention (Abboud et al., 2017). Cervical cancer is a particular concern
because Arab American women have a screening rate of 87% at best which still falls below the
Healthy People 2020 target of 93% screening (Dallo & Kindratt, 2015). With inadequate rates of
screening, prevention is that much more important. Cervical cancer is one of the only cancers
with a known primary cause, HPV infection (F X Bosch, Lorincz, Muñoz, Meijer, & Shah, 2002;
Klingelhutz & Roman, 2012; Muñoz, Castellsagué, de González, & Gissmann, 2006; Nour, 2009).
Cervical cancer is an aggressive disease once it takes hold of the human body, often detected in
advanced stages when women typically become symptomatic (Castle et al., 2009; Klingelhutz &
Roman, 2012; Lewis et al., 2010). Like most other cancers, the cells in the lining of the outer
part of the cervix or in the column-shaped glandular cells that line the cervical canal, mutate to
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override apoptosis, or programmed cell death, and multiply without control (F X Bosch et al.,
2002; Klingelhutz & Roman, 2012; Lewis et al., 2010). Eventually, this cluster of accumulated
out-of-control cells forms a mass, or tumor, which can break off and invade nearby tissue,
metastasizing in other parts of the body (F X Bosch et al., 2002; Klingelhutz & Roman, 2012;
Lewis et al., 2010).
Human Papillomavirus
HPV infection is the primary cause of cervical cancer (F. Xavier Bosch et al., 1995; Burd &
Dean, 2016). Human papillomavirus consists of 19 well-known strains, all of which carry varying
amounts of risk for the host (Burd & Dean, 2016; Castle et al., 2009). Of these 19 strains,
approximately 12 are classified as high risk by the International Agency for Research on Cancer,
such that the gene expression of HPV becomes deregulated and their abnormal life cycle is
associated with progression to cancer (Burd & Dean, 2016; Castle et al., 2009; Lewis et al.,
2010; Muñoz et al., 2003; Muñoz et al., 2006). HPV strains 16 and 18 are particularly identified
as carcinogenic as they are cited to cause the majority of HPV-related cancers, including
cervical, anal, vaginal, oropharyngeal, and more (Lewis et al., 2010; Muñoz et al., 2003).
HPV is a deadly virus that can result in viral infection in the host as a result of several risk
factors, including sexual relations with multiple partners, unprotected sex, smoking, lack of
access to vaccination and screening, and more (F X Bosch et al., 2002; Jain et al., 2009;
Walboomers et al., 1999). HPV is the single most common sexually transmitted infection
globally (F. Xavier Bosch et al., 1995).
HPV can be transmitted fairly easily through simple skin-to-skin sexual contact, including
genital and oral (Münger et al., 2004; Muñoz et al., 2006). Further, multiple strains of HPV can
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infect an individual at any given time (Münger et al., 2004; Muñoz et al., 2006). While most
sexually active individuals will contract HPV at some point in their lives, particularly if they are
subject to or participate in common risk factors, infection will only become cancerous in less
than 10% of individuals (Klingelhutz & Roman, 2012; Nour, 2009). Interestingly, this still
constitutes a large number of people as cervical cancer and other cancers attributed to HPV are
the 4th leading cause of death in women worldwide (F X Bosch et al., 2002; F. Xavier Bosch et
al., 1995; Castle et al., 2009).
In 50% of cases of HPV infection, the host immune system is able to attack and manage
the virus before it leads to carcinoma within one year (F X Bosch et al., 2002; Castle et al.,
2009). In 90% of cases, this occurs within two years (F X Bosch et al., 2002; Castle et al., 2009).
However, in individuals with weakened immune systems or as a result of other sociocultural or
environmental factors, this attack is not always possible or successful, resulting in persistent
infection for years or decades which ultimately results in cancer (Castle et al., 2009; Khan et al.,
2005; Klingelhutz & Roman, 2012). HPV, although not sufficient, is a necessary factor for the
development of cervical cancer.
Cervical Cancer Prevention
While the onset of cervical cancer in its early-stages does not typically boast drastic
symptoms, more advanced cervical cancer can be identified through excessive vaginal bleeding
after intercourse or between periods or after menopause, watery and bloody vaginal discharge
which may be heavy accompanied with a foul odor, and pelvic pain or abnormal pain during
intercourse (Moyer & Force*, 2012; Nour, 2009; Walboomers et al., 1999). When these
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symptoms arise, it is often at a stage where cervical cancer is difficult to manage and treat
(Nour, 2009). As such, while preventable, cervical cancer is a silent killer.
Fortunately, despite the potentially fatal outcome of certain high-risk HPV infection, this
virus is preventable through vaccination (Burd & Dean, 2016; Zhai & Tumban, 2016). The most
recent, and most commonly utilized, vaccine is Gardasil-9 which is known to protect against 9
strains of HPV, including high and low risk strains (Zhai & Tumban, 2016). This vaccine can be
administered in young women and girls as early as the age of 9 (Zhai & Tumban, 2016).
However, Gardasil-9 does not protect against HPV infection as effectively if an individual as
already been exposed to or contracted HPV ("Advisory Committee on Immunization Practices
(ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory
Committee on Immunization Practices (ACIP)," 2019; Zhai & Tumban, 2016). As such, health
professionals recommend administering the vaccine to adolescent girls before sexual activity
begins ("Advisory Committee on Immunization Practices (ACIP). Quadrivalent human
papillomavirus vaccine: recommendations of the Advisory Committee on Immunization
Practices (ACIP)," 2019). According to the Centers for Disease Control and Prevention (CDC),
which cuts off “late” at age 15 after which 3 shots are necessary for complete vaccination, the
ideal age to begin the vaccine regimen is ages 11-12 ("Advisory Committee on Immunization
Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory
Committee on Immunization Practices (ACIP)," 2019). While 13-14 is technically late, age 15 is
beyond the grace period ("Advisory Committee on Immunization Practices (ACIP). Quadrivalent
human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization
Practices (ACIP)," 2019).
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Further, Gardasil-9 is an intramuscular vaccine which must be administered in a series of
three injections over the course of 6 months, requiring repeated access to a healthcare facility,
providers, and the appropriate resources (Zhai & Tumban, 2016). Once vaccinated, an
individual can be effectively protected from HPV infection for up to 10 years (Franceschi et al.,
2006; Khan et al., 2005). However, as any vaccination is not 100% effective, this alone is an
imperfect method of HPV prevention. As such, routine screening for both HPV and cervical
cancer is recommended in women starting at age 21 throughout their reproductive life and
even after menopause (Abboud et al., 2017; Moyer & Force*, 2012).
Purpose
Cervical cancer largely affects women aged 30-50 which are arguably the most
productive years of one’s life (F. Xavier Bosch et al., 1995; Dallo & Kindratt, 2015; Nour, 2009).
Cervical cancer, along with its treatments, has been shown to decrease quality of life in
survivors and continue to cause adverse health outcomes such as changes in sexual and urinary
comfort, fertility, and mental health (Abboud et al., 2017; Nour, 2009). Although rates of
cervical cancer incidence have been slowly declining aby approximately 1% annually over the
past two decades, rates of mortality attributed to cervical cancer have remained stoic,
disproportionately affecting racial and ethnic minorities which has been well documented for
Black women, Native American women, and Hispanic women (Abboud et al., 2017). These
disparities seem to be related to several intersecting factors such as ethnicity and race,
socioeconomic status, access to insurance, and nativity, just to name a few (Abboud et al.,
2017; Dallo & Kindratt, 2015).
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The United States is witnessing a growing ethnic minority of Arab Americans with
Middle Eastern nativity (Echeverria & Carrasquillo, 2006; El-Sayed & Galea, 2009). However,
health-seeking behaviors and preventative medicine have been largely understudied in this
population due to their classification as White in census data collected by governmental
agencies (Ajrouch & Jamal, 2007). This erasure has primarily been perpetuated by two
sociopolitical factors. First, many Arab Americans, upon arrival to the United States in the late
twentieth century and early twenty-first century, actively pursued the White categorization as a
form of assimilation and belonging (Ajrouch & Jamal, 2007; Dallo, Booza, & Nguyen, 2015).
Second, after the terrorist attack on September 11th, 2001, which dramatically heightened
racism and fear targeted at Arab Americans and Muslims more generally, this invisibility in
research and data collection adversely contributed to a lack of understanding of their health
behaviors and access to care which were negatively impacted in the face of discrimination
(Abu-Ras & Abu-Bader, 2008, 2009; Dallo et al., 2018; Echeverria & Carrasquillo, 2006; El-Sayed
& Galea, 2009; Hassouneh & Kulwicki, 2007; Jamal A, 2008).
As such, only studies which actively seek out data on the Arab American immigrant
population specifically are able to assess their health disparities compared with their White
counterparts (Abboud et al., 2017; Dallo et al., 2015; Dallo & Kindratt, 2015; El-Sayed & Galea,
2009). This lack of research calls for a better understanding of health outcomes within this
population. The discrimination has only serve to worsen both their mental and physical health
and their ability to access appropriate and timely care without stigma or other sociocultural and
political barriers (Abu-Ras & Abu-Bader, 2008, 2009; Echeverria & Carrasquillo, 2006;
Hassouneh & Kulwicki, 2007). In order to address this problem, this study aims to examine HPV
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vaccination among Arab American immigrants in the United States compared to their White
counterparts.
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METHODS
Research Question
This study aims to assess health disparities in cervical cancer prevention through the
proxy of HPV vaccination in Arab American immigrant women in the United States compared
with White women, including White women born in the United States, born in Europe, or born
elsewhere. In order to do so, three primary variables of interest are assessed: ever having
received the vaccine, how many shots of the vaccine were received, and at what age the first
shot of the vaccine was received.
Statistical Plan
The primary researcher utilized data from the National Health Interview Survey (NHIS)
collected by the U.S. Census Bureau, from data releases from the years 2016, 2017, and 2018 to
conduct a secondary analysis. In summary, this is a national level database that collects crosssectional data over the course of a year with the aim of producing a racially/ethnically
representative sample. Due to sampling methods and time of day the survey is conducted,
older individuals tend to be oversampled. Details of the NHIS, its sampling design and methods,
and specific health topics collected were reported previously (National Center for Health
Statistics, 2012a). The primary researcher combined the “Persons” dataset and “Sample Adult”
dataset to obtain demographic and health data of interest. The dataset was subset by sex, age,
and race to only include White females aged 21-65. This subset allows inclusion of all women
eligible for a routine pap smear, or cervical cancer screening test, every three years and thus, at
the age of risk for cervical cancer. As this study aims to assess cervical cancer prevention
through HPV vaccination, this is the population of interest. Ultimately, we assessed 12 variables
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of interest: "REGIONBR", “MRACBPI2.x”, “SEX”, "AGE_P.x", "EDUC1", "YRSINUS", "R_MARITL.x",
"COVER", “DOINGLWA", "SHTHPV2", "SHPVDOSP", "AHPVAGE".
These variables correlate to the following demographic and health information: region
of birth, race, sex, age, education level, years spent in US, marital status, health insurance
coverage, employment status, if the woman has ever received an HPV vaccine, the number of
HPV shots she received, and the age at which she received her first shot. These demographic
characteristics have been shown in the literature as confounding variables that must be
controlled for when studying HPV vaccination as an indicator for cervical cancer prevention.
In terms of analysis, the region of birth variable was recoded to isolate women born in
the US, Europe, and Middle East as unique categories. All other individuals who identified as
racially White and in any other region of birth were categorized as “Other”. Of the 24,094
individuals included in the final dataset, after the data was subset for sex, age, and race, there
were only 115 individuals that identified the Middle East as their region of birth. In each of the
tables, descriptive statistics were compared for US, Europe, Middle East, and Other through a
frequency analysis using the chi-squared statistic for significance. Odds ratios with
accompanying 95% confidence intervals (CI) for the health outcomes of interest – ever having
received an HPV vaccine, the number of HPV shots received, and the age at first shot – were
calculated for Europe, Middle East, and Other utilizing the US as a reference group. We
controlled for covariates, which in this case were the demographic characteristics of interest
highlighted in the frequency analysis.
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RESULTS
The final data utilized in this study, from the NHIS years 2016-2018, included women
racially categorized as White, aged 21-65. As such, 24094 participants were included. Of these
24094 participants, 21580 recorded United States as their region of birth, 497 recorded Europe
as their region of birth, and only 115 recorded the Middle East as their region of birth. Another
1902 recorded various other geographic regions, including Russia, Central America, and South
America as their region of birth and were categorized as “Other”.
Out of all of the study participants who were women aged 21-65 (n = 32245) but not
restricted to any particular racial category, 119 women recorded the Middle East as their region
of birth. As such, there were 4 women who recorded the Middle East as their region of birth but
did not categorize themselves as White racially. These women were excluded from further
analyses due to the primary purpose of this study to assess health disparities among Arab
American women whose ethnic identity has become invisible by census categorization as
White.
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After conducting frequency analyses of the demographic and health information of
interest against region of birth, we obtained Tables 1 and 2.
Table 1: Demographic Information of Sample Adult Against Region of Birth – Subset to Female,
White, Aged 21-65*
Region of Birth
United
Middle
Characteristic
Europe
Other
pStates
East
(n = 497)
(n = 1902)
value
(n = 21580)
(n = 115)
Age (years), mean ± SD
44.8 ± 13.2 47.0 ± 11.7 43.6 ± 12.3 43.1 ± 12.0 <0.001
Year(s) Spent in the
<0.001
United States, n (%)
<5
NA
39 (7.9)
28 (24.3)
185 (10.0)
5-10
NA
22 (4.5)
19 (16.5)
162 (8.7)
10-15
NA
44 (8.9)
6 (5.2)
243 (13.1)
>15
NA 387 (78.7)
62 (53.9)
1269 (68.3)
Education, n (%)
<0.001
Less than high school
1258 (6.4)
22 (4.8)
10 (8.9)
548 (30.5)
High school graduate
4334 (22.1)
90 (19.8)
17 (15.2)
400 (22.3)
Some college
5346 (27.2)
99 (21.8)
21 (18.8)
282 (15.7)
Bachelor or higher
8686 (44.3) 243 (53.5)
64 (57.1)
565 (31.5)
Marital status, n (%)
<0.001
Married
10930 (50.7) 274 (55.2)
78 (67.8)
1033 (54.5)
Widowed/Sep/Divorced
4873 (18.7)
67 (13.5)
19 (16.5)
414 (21.8)
Living with partner
1719 (8.0)
29 (5.8)
0 (0.0)
133 (7.0)
Never married
4025 (18.7) 126 (25.4)
18 (15.7)
317 (16.7)
Health Insurance, n (%)
<0.001
Private
15420 (73.8) 360 (75.2)
72 (63.7)
929 (50.3)
Medicaid, Other public
2690 (12.8)
44 (9.2)
18 (15.9)
317 (17.2)
Other coverage
1101 (5.3)
39 (8.1)
5 (4.4)
80 (4.3)
Uninsured
1700 (8.1)
36 (7.5)
18 (15.9)
520 (28.2)
Employment Status, n (%)
<0.001
Working for pay
14996 (69.5) 340 (68.4)
57 (49.6)
1145 (60.2)
Looking for work
575 (2.7)
15 (3.0)
6 (5.2)
68 (3.6)
Not working for pay
6003 (27.8) 142 (28.6)
52 (45.2)
688 (36.2)
* Numbers may not sum to totals due to missing data, and column percentages may not sum to
100% due to rounding.
This table compares the unadjusted associations between region of birth and
demographic variables (n = 24094). There was a statistically significant relationship between
age and region of birth such that European-born participants had the oldest average age at
15

approximately 47 years while Middle Eastern-born participants and participants born in Other
regions had the youngest average age at approximately 43 years.
Further, there was a statistically significant relationship between region of birth and
years spent in the United States such that nearly 80% of European-born participants had lived
in the United States for over 15 years while just over 50% of Middle Eastern-born participants
had lived in the United States for over 15 years and nearly 25% had lived in the United States
for less than 5 years. Participants born in the United States were excluded from this measure in
the original dataset.
In terms of education, Middle Eastern-born participants were the most highly educated
group with nearly 60% of participants boasting a bachelor’s degree or higher. Alternatively,
more than 30% of participants born in Other geographic regions had less than a high school
education. European-born participants had comparable percentages to Middle Eastern born
participants such that almost 55% had received a bachelor’s degree or higher followed by the
United States in which approximately 45% of participants had received a bachelor’s degree or
higher.
Further, there was a statistically significant relationship between marital status and
region of birth such that Middle Eastern-born participants had the highest percentage of
married women at nearly 70% and the lowest percentage of never married women at around
15%. Interestingly, not a single one of the 115 participants recorded living with a partner while
unmarried. United States-born participants, European-born participants, and participants born
in Other geographic regions had similar percentages of married women at around 50-55% of
participants. United States-born participants had the highest percentage of women living with a
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partner while unmarried at 8% and European-born participants had the highest percentage of
unmarried women at over 25%.
In terms of health insurance coverage, a majority of US-born participants, Europeanborn participants, Middle Eastern-born participants, and participants born in Other regions had
private insurance at approximately 74%, 75%, 64%, and just over 50%, respectively. However,
Middle Eastern born participants and participants born in Other geographic regions had the
highest percentage of individuals utilizing Medicaid or another form of public health insurance
at approximately 16% and 17%, respectively. Further, these two groups had significantly higher
rates of uninsured participants than their US-born and European-born counterparts at around
16% and 28%, respectively.
Finally, in terms of employment, Middle Eastern-born participants had the significantly
lowest percentage of women working for pay at just below 50% and the highest percentage of
women not working for pay at approximately 45%. Further, Middle Eastern-born participants
had the highest percentage of women looking for work out of all the groups at over 5%.
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Table 2: HPV Vaccination Status – Descriptive Statistics*
Region of Birth
United
Characteristic
Europe
Middle East
Other
p-value
States
(n = 497)
(n = 115)
(n = 1902)
(n = 21580)
Ever received
HPV Vaccine, n
*(n = 20144)
*(n = 456)
*(n = 100)
*(n = 1739)
<0.001
(%)
Yes
2630 (13.1)
32 (7.0)
6 (6.0)
152 (8.7)
No
17514 (86.9)
424 (93.0)
94 (94.0)
1587 (91.3)
Number of HPV
shots received, n
*(n = 2315)
*(n = 28)
*(n = 5)
*(n = 129)
0.042
(%)
1
410 (17.7)
8 (28.6)
4 (80.0)
37 (28.7)
2
348 (15.0)
5 (17.9)
0 (0.0)
20 (15.5)
All
1557 (67.3)
15 (53.6)
1 (20.0)
72 (55.8)
Age at first HPV
shot (years),
18.7 ± 6.5
21.4 ± 8.0
19.6 ± 5.0
21.2 ± 7.7
0.381
mean ± SD
* Numbers may not sum to totals due to missing data, and column percentages may not sum to
100% due to rounding.
This table compares the unadjusted associations between region of birth and health
outcomes of interest (n = 24094). There was a statistically significant relationship between ever
having received and HPV vaccine and region of birth such that United States-born participants
had the highest percentage of women who had ever received the vaccine at approximately 13%
while Middle Eastern-born participants had the lowest percentage at 6%.
Further, Middle Eastern-born participants had a significantly lower percentage of
women who had completed the HPV vaccine regimen at just 20% compared with their White
counterparts at approximately 67%, 54%, and 56% for United States-born participants,
European-born participants, and participants born in Other regions, respectively. None of the
Middle Eastern-born participants had received two shots and 80% had received just one.
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Notably, there is a small sample size for this data such that of the 6 Middle Eastern-born
individuals who reported receiving the vaccine, only 5 indicated the number of shots they
received and the age at their first shot. Similarly, only 2315 out of the 2630 United-States born
participants that reported receiving a vaccine also reported how many shots and age at first
shot. This is true for European-born participants and participants born in Other regions at 28
out of 32 and 129 out of 152 participants, respectively. These small sample sizes compromise
the significance and generalizability of this data.
Finally, the average age at which participants received their first HPV shot was not
statistically different across different geographic regions of birth with United States-born
participants having an average age of approximately 19, Middle Eastern-born participants
having an average age of approximately 20, and European-born participants and participants
from Other regions having an average age of approximately 21. All of these groups had an
average age considered late by the CDC which cuts off “late” at age 15.
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After calculating odds ratios with accompanying 95% CIs of the health information of
interest against region of birth, we obtained Table 3.
Table 3: Associations between HPV Vaccination Status and Region of Birth – United States as
reference group*
Region of Birth
Characteristic
Europe
Middle East
Other
OR (95% CI)
(n = 456)
(n = 100)
(n = 1739)
Received HPV
0.503 (0.350, 0.722) 0.435 (0.186, 0.971) 0.638 (0.537, 0.757)
Vaccine
Completed HPV
0.562 (0.266, 1.187) 0.122 (0.014, 1.091) 0.615 (0.430, 0.880)
Vaccine Regimen
First HPV Shot
Before Age 15
0.436 (0.103, 1.849)
NA
0.950 (0.574, 1.567)
(Not Late)
* Numbers may not sum to totals due to missing data, and column percentages may not sum to
100% due to rounding.
This table assess the adjusted odds ratios between region of birth and health outcomes
of interest, controlled for the demographic variables highlighted in Table 1. Middle Easternborn participants had the statistically significant lowest odds of ever having received an HPV
vaccine such that they had 0.435 times the odds of receiving the vaccine of United States-born
participants. This is lower than European-born participants who had 0.503 times the odds of
United States-born participants and participants from Other regions who had 0.638 times the
odds of United States-born participants.
Further, while not statistically significant due to the small sample sizes as explained in
the interpretation for Table 2, Middle Eastern-born participants had the lowest odds of
completing the HPV vaccine regimen such that they had 0.122 times the odds of completing the
vaccine regiment of United States-born participants. Participants from Other regions had a
statistically significant lower odds of completing the vaccine regimen compared with United
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States-born participants such that they had 0.615 times the odds of completing the vaccine
regimen.
Finally, due to the small sample size, not a single one of the 6 Middle Eastern-born
participants who reported ever having received the vaccine reported receiving the first HPV
shot before the age of 15, making it impossible to calculate an odds ratio, reported as “NA”.
Alternatively, although not statistically significant, European-born participants and participants
born in Other regions had lower odds of receiving the first HPV shot at the age of 15 than
United States-born participants. While European-born participants were 0.436 had 0.436 times
the odds of United States-born participants, participants born in Other regions had 0.950 times
the odds of United States-born participants of receiving the HPV vaccine before the age of 15.
Overall, nativity seems to be an indicator of poorer participation in preventative health
behaviors as indicated by patterns of HPV vaccination. However, these results are limited by
small sample sizes and as such, are not statistically significant apart from ever having received
the HPV vaccine.
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DISCUSSION
Analysis
In the past two decades, tensions and discrimination surrounding the ethnic Arab
minority in the United States has increased for various reasons including the events of
September 11, 2001 and the worsening relations between the United States and the Middle
East as a result of the Iraq war, Trump’s “Muslim ban”, and more (Abu-Ras & Abu-Bader, 2008,
2009; Echeverria & Carrasquillo, 2006; El-Sayed & Galea, 2009; Hassouneh & Kulwicki, 2007;
Jamal A, 2008). Consequently, racism has heightened toward Arab American immigrants in the
United States which has adverse mental and physical effects and can compromise access to
health benefits, comfort with healthcare providers, and ultimately lead to adverse health
outcomes (Abu-Ras & Abu-Bader, 2009; Hassouneh & Kulwicki, 2007; Jamal A, 2008).
Cervical cancer is a particular concern because Arab American women have a screening
rate of 87% at best which still falls below the Healthy People 2020 target of 93% screening
(Dallo, 2015). As such, this paper assessed HPV vaccination among Arab American immigrants in
the United States compared with their other White counterparts as proxy for cervical cancer
prevention.
This study, which is a secondary analysis of survey data from the National Health
Interview Survey (NHIS) from the years 2016, 2017, and 2018, includes 24094 participants who
identified as racially White, female, and between the ages of 21 and 65. Of these 24094
participants, 21580 recorded United States as their region of birth, 497 recorded Europe as
their region of birth, and only 115 recorded the Middle East as their region of birth. Another
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1902 recorded various other geographic regions, including Russia, Central America, and South
America as their region of birth and were categorized as “Other”.
Further, out of all of the study participants who were women aged 21-65 (n = 32245)
but not restricted to any particular racial category, 119 women recorded the Middle East as
their region of birth. As such, there were 4 women who recorded the Middle East as their
region of birth but did not categorize themselves as White racially. These women were
excluded from further analyses this study primarily aims to assess health disparities among
Arab American women whose ethnic identity has become invisible by census categorization as
racially White.
Demographic Characteristics
Overall, the results posit that nativity plays a significant role in education level, marital
status, health insurance coverage, and employment status, among other variables. Some of the
most noteworthy results indicated that Middle Eastern-born participants had the highest
percentage of individuals living in the United states for less than 5 years at 25%. This
contributes to the existing literature which claims that Arab Americans are one of the fastest
growing minority groups in the United States today (Dallo et al., 2015; Dallo & Kindratt, 2015;
Singh & Hiatt, 2006).
Further, despite being the most highly educated group with nearly 60% of participants
having a bachelor’s degree or higher, Middle Eastern-born participants had the higher
percentage of participants looking for work, at approximately 5%. Further, compared to their
White counterparts, Middle Eastern-born participants had the lowest percentage of women
working for pay, just below 50%.
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Further, Middle Eastern-born participants had the highest percentage of married
women at nearly 70% and the lowest percentage of never married women at around 15%.
Interestingly, not a single one of the 115 participants recorded living with a partner while
unmarried. While not explicitly assessed through this study, previous literature shows a more
conservative culture among Arab Americans with regard to sexual activity which is further
supported by this statistic (Abboud, Jemmott, & Sommers, 2015; P, 2008).
Finally, Middle Eastern-born participants did not fare as well their US-born or Europeanborn counterparts in terms of health insurance coverage such that approximately 16% of
participants relied on Medicaid or another form of public health insurance rather than private
insurance and another 16% were uninsured. In contrast, only 8% of US-born and European-born
participants reported being uninsured.
Health Outcomes
The results regarding our health outcomes of interest, ever having received an HPV
vaccine, number of shots received, and age at first shot, also showed disparities across varying
regions of birth. There was a statistically significant relationship between ever having received
and HPV vaccine and region of birth such that United States-born participants had the highest
percentage of women who had ever received the vaccine at approximately 13% while Middle
Eastern-born participants had the lowest percentage at just 6%. When adjusted for the
demographic characteristics outlined in Table 1, Middle Eastern-born participants had the
statistically significant lowest odds of ever having received an HPV vaccine such that they had
0.435 times the odds of receiving the vaccine of United States-born participants. This is lower
than European-born participants who had 0.503 times the odds of United States-born
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participants and participants from Other regions who had 0.638 times the odds of United
States-born participants.
Further, when unadjusted, Middle Eastern-born participants had a significantly lower
percentage of women who had completed the HPV vaccine regimen at just 20% compared with
their White counterparts at approximately 67%, 54%, and 56% for United States-born
participants, European-born participants, and participants born in Other regions, respectively.
None of the Middle Eastern-born participants had received two shots and 80%, or 4 out of 5,
had received just one. After adjusting for the demographic variables in Table 1, the odds of
completing the HPV vaccine were lowest for Middle Easter-born participants such that they had
0.122 times the odds of completing the vaccine regiment of United States-born participants.
Finally, while all the groups had similar average ages of receiving the first vaccine, this
age was above the CDC recommended cut off for receiving the vaccine “late” at age 15. In
terms of differing odds, due to the small sample size, not a single one of the 6 Middle Easternborn participants who reported ever having received the vaccine reported receiving the first
HPV shot before the age of 15, making it impossible to calculate an odds ratio, as the technical
odds for receiving the first shot before the age of 15 for United States-born participants are
infinitely higher than for Middle Eastern-born participants according to this sample.
Notably, there is a small sample size for this data such that of the 6 Middle Eastern-born
individuals who reported receiving the vaccine, only 5 indicated the number of shots they
received and the age at their first shot. Similarly, only 2315 out of the 2630 United-States born
participants that reported receiving a vaccine also reported how many shots and age at first
shot. This is true for European-born participants and participants born in Other regions at 28

25

out of 32 and 129 out of 152 participants, respectively. These small sample sizes compromised
the significance and generalizability of this data overall which in turn affected our ability to
calculate and interpret odds ratios for the health outcomes of interest.
Conclusions
Ultimately, this study posits that nativity is an indicator of poorer participation in
preventative health behaviors as indicated by patterns of HPV vaccination. However, these
results are limited by small sample sizes and as such, are not statistically significant outside of
ever having received the HPV vaccine. While Arab American women were more highly educated
than any other category, they had the lowest rates of health insurance coverage and
employment. While not explicitly assessed in this study, these results hint at social, cultural,
economic, and political factors which may be affecting access to preventative health care, and
may be affecting overall health outcomes as a result, within this population.
Limitations
Despite the inclusion of three years of data, there are only 115 women included in the
primary category of interest, Middle East as region of birth. Further, only 100 of these women
reported any data regarding HPV vaccination status. Similarly, for all other categories of region
of birth, only a fraction of the participants reported any data regarding HPV vaccination. As
such, there is very little data at our disposal for the overall assessment of health outcomes
across these populations which limits our ability to obtain statistical significance in the final
evaluations.
Further, this study only assessed cervical cancer prevention through the proxy of HPV
vaccination status and does not analyze cervical cancer screening and the benefits of early
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detection on cervical cancer incidence. Due to a lack of health information in the 2016 and 2017
datasets regarding cervical cancer screening, a more comprehensive assessment of overall
prevention of cervical cancer mortality was not conducted.
Finally, due to a lack of data, overall rates of HPV vaccination in the United States among
Arab Americans generally were not assessed due to a lack of information on ethnicity explicitly.
Rather, this study was limited to Arab American immigrants specifically as the researchers had
to utilize Middle Eastern nativity as a proxy for Arab American categorization.
Future Directions
The limited research conducted with this population calls for a better understanding of
preventative health behaviors among Arab American immigrants. In particular, there needs to
be more research regarding access to HPV vaccination due to its function as a primary
contributor to cervical cancer prevention. The purpose of this study is to quantify the disparities
in access to HPV vaccination among Arab American immigrants with the hope that this research
may be utilized to inform interventions that bridge the disparities in access to cervical cancer
prevention through HPV vaccination or even simply identify that these disparities exist to begin
with, highlighting a gap in health literature.
In the future, these questions can also be expanded to individuals with United States
nativity who ethnically identify as Arab American. Ultimately, this study is not only a call to
action for more comprehensive and ethnically-inclusive health literature, but also for more
inclusive categorization in census data and thoughtful assessments of the varying lived
experiences in the United States.
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